Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a

Charles River Laboratories International, Inc. (CRL) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/FCF of 45.4×. Over the past ten years it has ranged from 13.0× (April 2025) to 56.0× (October 2021); the current reading is higher than 90% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 22.8× (0.91%)
FY2024 23.0× (41.55%)
FY2023 39.3× (14.53%)
FY2022 46.0× 14.38%
FY2021 40.2× 8.20%
FY2020 37.2× 39.20%
FY2019 26.7× 16.58%
FY2018 22.9× (13.40%)
FY2017 26.5× 46.80%
FY2016 18.0× (2.06%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 35.9× 28.82%
Mar 2026 27.9× 22.48%
Dec 2025 22.8× 27.94%
Sep 2025 17.8× 7.19%
42 more quarters

Against its own ten years

Low 13.0× High 56.0×
Ten-year median 27.2×
Current reading's percentile 89

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on CRL